Yield curve fear is back
One of the most reliable recession indicators in markets is starting to flash red. Investors should beware


Between war and inflation, markets have a lot to worry about. So fretting over an arcane-sounding bond market phenomenon may not be top of your priority list. But if history is any judge, it should be. We’re talking about the “inverted yield curve”. We explain exactly what a yield curve is here, but, put simply, when a yield curve inverts, it means that the interest rate on long-term government bonds is lower than that on short-term ones. That’s a sign that the market thinks interest rates will have to fall in the future, which implies slower growth, or even a recession.
The good news is that the most significant bit of the yield curve, the gap between the two-year US Treasury bond and the ten-year, is yet to invert. As of Monday, the ten-year yields around 2.3% while the two-year yields 2.1%. The bad news is that bond investors are betting that within three months, the two-year yield will be above the ten. And in the last 40 years, every time that’s happened, a recession has followed within 24 months.
It’s probably not different this time
No indicator is perfect and we only have a limited data set to draw on (recessions don’t happen that often). So it could be different this time. For example, Morgan Stanley strategists believe the curve will indeed invert, but that this time it won’t signal a recession, because of distortions related to quantitative easing. However, as Eoin Treacy notes on FullerTreacyMoney, “rationalisations for why this time is different crop up whenever the yield curve approaches inversion”. But what could prevent the inversion?
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Inversion is typically driven by markets fearing that Fed will raise interest rates too aggressively for the economy to handle. That’s exactly what’s happening now. So if anything prevents the inversion, it’s likely to be the Fed either getting cold feet, or clear evidence that the economy is genuinely running hot enough to handle rate hikes.
Perhaps a more important question for investors is: if we do face a recession, is there anything you should do?
Recessions are undeniably bad news for stockmarkets. Robert Armstrong, writing in the Financial Times, cites Bank of America’s Stephen Suttmeier, who reckons that “during the average recession, the S&P 500 drops by a third over 13 months”. Yet history also suggests that markets typically don’t hit a top until the inversion has happened, which implies the US market could still have a way to rise before it goes down. So despite the indicator’s strong track record, trying to use it to time the market is futile. A better bet is to make sure you have cash to take advantage of any opportunities that arise; and focus on buying at low valuations, rather than predicting the future.
Sign up for MoneyWeek's newsletters
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.
John Stepek is a senior reporter at Bloomberg News and a former editor of MoneyWeek magazine. He graduated from Strathclyde University with a degree in psychology in 1996 and has always been fascinated by the gap between the way the market works in theory and the way it works in practice, and by how our deep-rooted instincts work against our best interests as investors.
He started out in journalism by writing articles about the specific business challenges facing family firms. In 2003, he took a job on the finance desk of Teletext, where he spent two years covering the markets and breaking financial news.
His work has been published in Families in Business, Shares magazine, Spear's Magazine, The Sunday Times, and The Spectator among others. He has also appeared as an expert commentator on BBC Radio 4's Today programme, BBC Radio Scotland, Newsnight, Daily Politics and Bloomberg. His first book, on contrarian investing, The Sceptical Investor, was released in March 2019. You can follow John on Twitter at @john_stepek.
-
Barclays begins paying up to £100 compensation to customers after banking outage
Barclays will pay up to £7.5 million in compensation to customers after its banking services were disrupted by an IT outage
By Daniel Hilton Published
-
Review: Shangri-La Paris – an ode to the world’s best food
Natasha Langan enjoys fine French and Chinese cuisine at the Shangri-La Paris
By Natasha Langan Published
-
Falling revenues and mounting debt spell trouble for Jumia Technologies
Struggling African e-commerce platform Jumia Technologies looks headed for the exit, says Dr Matthew Partridge.
By Dr Matthew Partridge Published
-
Next reports £1 billion in annual profits for the first time – what's next for the retailer?
Clothing retailer Next has become only the fourth member of its sector to surpass £1 billion in annual profits. What does this mean for the company's future?
By Dr Matthew Partridge Published
-
Best of British bargains: cash in on undervalued companies in the UK stock market
Opinion Michael Field, Chief Equity Market Strategist, EMEA, Morningstar, selects three attractive UK stocks where he'd put his money
By Michael Field Published
-
Building firm Keller presents low debt and ample scope for growth
Geotechnical contractor Keller, which supports vital global infrastructure, boasts rising profits and a cheap valuation
By Dr Mike Tubbs Published
-
PZ Cussons share price down 75% in last decade – why it's one to watch
Opinion Once-strong consumer-goods business PZ Cussons is out of favour with the market. That spells opportunity for investors, says Jamie Ward
By Jamie Ward Published
-
Cash in on the biotech sector with specialist trust BioPharma
Opinion BioPharma has an attractive niche in lending to asset-rich biotechnology companies
By Rupert Hargreaves Published
-
India's stock market decline wipes out $1.3 trillion in market value – can investors stay optimistic?
More than $1 trillion has been wiped off from India's stock market after investors turn to China. Has the emerging-market darling hit rock bottom?
By Alex Rankine Published
-
Pensions revolution: how to profit from the trends shaping the UK pension system
The UK pension system is one of the biggest in the world. Big changes are under way, says Rupert Hargreaves
By Rupert Hargreaves Published